BRIEF-U.S. FDA approves supplemental New Drug Applications for three Type 2 diabetes medicines

* U.S. FDA approves supplemental new drug applications to include landmark data in product labels for synjardy (empagliflozin/metformin hydrochloride), synjardy xr (empagliflozin/metformin hydrochloride extended-release) and glyxambi (empagliflozin/linag